Case study
Best-in-Class LRRK2 Therapies for Parkinson’s Disease
Challenge
Following Alzheimer’s disease, Parkinson’s disease is the second most common neurodegenerative disorder in the US. LRRK2 is one of the most promising drug targets for Parkinson’s disease. There are currently some drug candidates in clinical trials, but no FDA-approved drug. The goal: to pioneer the first approved therapy in this large and critical market.
Solution & Impact
BIOPTIC AI quickly identified a chemically novel 0.86 uM LRRK2 inhibitor from a vast chemical space of 39B molecules. This discovery brings us closer to delivering a best-in-class solution for an underserved patient population.
Chemical spase
39B
Search time
4H
Tested
87 compounds
Total cost
$17K
Novelty (Tanimoto ECFP4)
max 0.4
Hit rate (<10 μM)
4.6%
Best hit
0.86 μM
Partner with Bioptic
Expanding the scope of your research.